Pigment epithelium-derived factor as a new diagnostic marker for melanocytic tumors

Kurume Medical Journal

Volumn 52, Issue 3, 2005, Pages 81-87

  Tsuru, Masaki ^a   Arima, Nobuyuki ^a,b   Toyozumi, Yasuo ^c   Kato, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry and angiogenesis; Malignant melanoma; Melanocytic nevus; Pigment epithelium derived factor (PEDF)

Indexed keywords

ANGIOGENESIS INHIBITOR; MELAN A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMB 45; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN S 100;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOCYTE; MELANOCYTIC TUMOR; MELANOMA; METASTASIS POTENTIAL; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS;

EYE PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NERVE GROWTH FACTORS; NEVUS, PIGMENTED; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 32844455398     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.52.81     Document Type: Article

References (37)

1. Folkman J, Watson M, Ingber D, and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (Lond) 1989; 339:58-61.
2. Holmgren L, O'Reilly MS, and Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
3. Carmeliet P, and Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
4. Folkman J, Shochat SJ, Strand RD, and Fellows KE. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
6. Carmelist P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-395.
7. Giri D, Ropiquet F, and Ittmann M. Alteration in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999; 5:1063-1071.
8. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-416.
9. Folkman J. Angiogenesis agents. In: Cancer principles and practice of oncology, eds. DeVita VT, Hellman S, and Rosenberg SA, 6th edn, Lippincot Williams & Wilkins, Philadelphia, pp 509-519, 2001.
10. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994; 79:315-328.
11. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87:6624-6628.
12. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285.
13. Tombran-Tink J, Chader GG, and Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53:411-414.
14. Tombran-Tink J, Mazuruk K, Rodriguez IR, Chung D, Linker T et al. Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis 1996; 2:11.
15. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9:774-780.
16. Cao W, Tombran-Tink J, Chen W, Mrazek D, Elias R et al. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J Neurosci Res 1999; 57:789-800.
17. Tombran-Tink J, and Johson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989; 30:1700-1707.
18. Gao G, Li Y, Gee S, Dudley A, Fant J et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002; 277:9492-9497.
19. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (Wash DC) 1999; 285:245-248.
20. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188:253-263.
21. Stellmatch V, Crawford SE, Zhou W, and Bouk N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98:2593-2597.
22. Raisler BJ, Berns KI, Grant MB, Beliacv D, and Hauswirth WW. Adeno-associated virus type-2 expression of pigment epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002; 99:8909-8914.
23. Houenou LJ, D'Costa AP, Li L, Turgeon VL, Enyadike C et al. Pigment epithelium-derived factor promote the survival and differentiation of developing spinal motor neurons. J Comp Neurol 1999; 412:506-514.
24. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001; 114:4421-4428.
25. Guan M, Yam HF, Su B, Chan KP, Pang CP et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003; 56:277-282.
26. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64:5664-5671.
27. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlated with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64:3533-3537.
28. Miyagishi D, Ohno-Matsui K, Amagasa T and Morita I. Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenetic factor in human oral squamous cell carcinoma cell line. Cancer Lett 2003; 196:77-85.
29. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004; 164:1225-1232.
30. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, and Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003; 26:28-38.
31. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K et al. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40:252-259.
32. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW et al. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004; 11:325-332.
33. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004; 64:5632-5642.
34. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J et al. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003; 8:72-79.
35. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003; 3:559-570.
36. Dredge K, Dalgleish AG, and Marriott JB. Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 2003; 4:667-674.
37. Soengas MS, and Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.